Jazz Pharmaceuticals (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy. In oncology, its marketed medicines include Vyxeos® (daunorubicin and cytarabine liposome) for newly diagnosed therapy-related acute myeloid leukemia, Zepzelca® (lurbinectedin) for small cell lung cancer, and Defitelio® (defibrotide) for hepatic veno-occlusive disease. Through the acquisition of GW Pharmaceuticals in 2021, Jazz added Epidiolex® (cannabidiol) to its portfolio for rare epilepsy syndromes.
Founded in 2003 and headquartered in Dublin, Ireland, Jazz maintains research, development and commercial operations across North America, Europe and Asia-Pacific. The company expanded its capabilities through a series of strategic mergers and acquisitions, including the 2011 combination with Azur Pharma and the 2021 purchase of GW Pharmaceuticals, strengthening its position in both neurology and oncology.
Under the leadership of President and Chief Executive Officer Bruce C. Cozadd, Jazz Pharmaceuticals continues to advance its clinical pipeline with investigational candidates in sleep disorders, neurodevelopmental conditions and various cancer indications. The company emphasizes global collaboration and strategic partnerships to accelerate the delivery of novel therapies to patients worldwide.
